We are proud to announce that three members of our team have been recognized by Managing IP. Dr. Jacqueline Lui and Ms. Pauli Wong have been recognized as a Patent Star and Mr. Eddie Ho as a Rising Star by ManagingIP. These prestigious awards acknowledge their exceptional expertise and invaluable contributions to the field of intellectual property.

Dr. Lui is widely recognized as a leading expert in patent law, specializing in cross-jurisdiction patent prosecution and strategy. With over 20 years of experience in IP, she has provided invaluable guidance to startups, Fortune 500 companies, and HK/Nasdaq-listed companies. Her expertise encompasses various critical areas, including IP strategy, portfolio management, technology transfer, due diligence, and enforcement. Dr. Lui's exceptional track record and unwavering commitment to excellence have solidified her reputation as a trusted advisor in the field.

Ms. Pauli Wong oversees the patent drafting team at Eagle IP and assists local and international clients with patent prosecution across a wide range of technology fields. She helps clients navigate IP rights, portfolio management, and global filing strategy for innovations in areas like biotechnology, medical devices, and robotics. Pauli is passionate about empowering Hong Kong innovators, leveraging her ability to quickly understand new technologies, meticulous prosecution skills, strategic business acumen, and commitment to client service.

Mr. Eddie Ho is a qualified Chinese Patent Attorney and has quickly amassed extensive experience drafting and prosecuting patent applications in a broad range of areas, including biology, biotechnology, medical devices, diagnostics, material science, engineering, and software. He helps inventors and companies manage and navigate complex patent portfolios and is exceptionally strong at inter-disciplinary technologies.

Let us come together to celebrate this well-deserved accolade for Dr. Jacqueline Lui, Ms. Pauli Wong, and Mr. Eddie Ho and to recognize their exceptional dedication to the dynamic world of intellectual property.

我們過去活動

Recommended Insights

Beijing IP Court Reverses CNIPA Decision and Upholds Ozempic® semaglutide patent in China as VALID based on Novo Nordisk’s Post Filing Data

2024年6月27日
Recently, all eyes have been on China as the fundamental patent covering semaglutide, the active ingredient in Ozempic® and Wegovy®, will expire on March 20, 2026. It goes without saying that generics are ramping up bigtime in China (and also around the world), preparing to manufacture and sell this blockbuster drug to one of the […]

Introducing the New USPTO Cancer Moonshot Expedited Examination Pilot Program

2023年1月10日
Starting from February 1, 2023, the USPTO will begin the new Cancer Moonshot Expedited Examination Pilot Program that advances out-of-turn applications that are directed to oncology or smoking cessation. This new program will replace the Cancer Immunotherapy Pilot Program that has been in place since 2016, and covers more technologies than only cancer immunotherapies. Applications […]

Finally a unified “Court of Appeal” for technology IP in China

2019年1月22日
On October 26, 2018, China’s Supreme People’s Court (“SPC”) received approval to establish a specialized intellectual property court within the SPC to handle appeal cases involving technology-related IP for both civil (e.g., patent infringement) and administrative (e.g., patent invalidity) judgments. Technology-related IP includes invention patents, utility models, new plant species, IC design, trade secret, software, […]

First ever Invalidation decision on an RNAi Invention patent in China

2023年12月4日
Decision on Examination of Request for Invalidation (No. 58530) In one of China’s Top 10 Patent Re-examination / Invalidation cases of 2022, an invalidation decision on a patent claiming Hepatitis B Virus (HBV) RNAi compositions (No. 58530) by the Patent Re-examination Board (the “Board”) sheds light on the standard for post filing data for rejections […]
Top crossarrow-right